U.S. Water Utilities Stock News

The United States market has remained flat over the last week but has experienced a significant 29% increase over the past year, with earnings forecasted to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they may indicate strong confidence in the company's future prospects from those who know it best.

If you are wondering whether Globant's current share price reflects its true worth, this breakdown is designed to help you put some clear numbers around that question. The stock last closed at US$41.02, with returns of an 18.5% decline over 7 days and a 7.9% decline over 30 days, contributing to a 35.0% decline year to date and a 65.5% decline over 1 year. These moves sit alongside a longer 3 year return of a 73.1% decline and an 81.1% decline over 5 years, which may influence how the market...

Wondering whether Atlantic Union Bankshares at around US$38.10 is offering fair value or a potential mispricing opportunity for your portfolio right now. The stock has posted returns of 1.4% over the last 7 days, 9.5% over 30 days, 7.3% year to date, 42.9% over 1 year and 67.4% over 3 years, with a 5 year return of 15.4%. This naturally puts a spotlight on what you might be paying for that performance today. These moves sit against a backdrop of ongoing news flow around U.S. regional banks,...

Kaltura (KLTR) has packed the past few weeks with AI-focused product launches, regional infrastructure expansion, and high profile partnerships, putting its agentic digital experience strategy squarely in focus for current and prospective shareholders. See our latest analysis for Kaltura. Despite a busy April calendar of AI product releases, infrastructure rollouts, and conference appearances, Kaltura’s recent 30 day share price return of 18.40% follows a 90 day share price return decline of...

If you are wondering whether Cheesecake Factory at around US$62.68 is still reasonably priced or already baking in too much optimism, it helps to break the story into the numbers behind the share price. The stock has seen mixed recent performance, with a 0.9% decline over the last week but gains of 15.3% over the past month, 18.7% year to date and 26.9% over the last year, while the 3 year return sits at 108.0% and the 5 year return at 11.9%. Recent news coverage has focused on Cheesecake...

If you are wondering whether Lumen Technologies at US$8.72 still offers value or is already priced for optimism, this article breaks down what the current share price may be implying about the business. The stock has been volatile recently, with a 0.1% decline over the last week, a 30.7% gain over the last month, a 13.4% return year to date, a 144.3% return over 1 year and a very large 272.6% return over 3 years, set against a 24.8% decline over 5 years. Recent headlines have continued to...

VisionWave Holdings, Inc. recently appointed Shayna Quinn, a 33-year-old executive with extensive M&A and transportation technology experience, to its Board as an independent director, effective April 16, 2026, following a US$44.15 million shelf registration for up to 6,148,943 common shares. Quinn’s background in post-deal integration, market expansion, and regulatory coordination may influence how VisionWave pursues future transactions and operational scale-up efforts. We’ll now explore...

Public Storage (PSA) opened 2026 with Q1 revenue of US$1.2 billion, basic EPS of US$2.72, and funds from operations of US$772.7 million, setting a clear marker for how the storage REIT is entering the new year. Over the past five quarters, revenue has moved from US$1.19 billion in Q1 2025 to US$1.22 billion in Q1 2026, while basic EPS shifted from US$2.04 to US$2.72 over the same span. This gives investors a clear view of how the top line and per share results have tracked through recent...

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD. Following the transaction, Amicus has been delisted from the Nasdaq and removed from major indices including the S&P and Russell families. The deal ends Amicus's status as an independent public company and sets up integration of its rare disease portfolio into BioMarin. For investors who followed Amicus Therapeutics at a share price of $14.49 and a value score of 3, the...

This article examines whether Compass, trading at around US$7.89, represents a bargain or is already pricing in its current story, and explores what that price might imply about value. The stock has delivered mixed returns, with a 0.8% move over the last week, 11.4% over the last month, a 24.9% decline year to date, and a 3.4% return over the past year, which can shape how investors think about both potential upside and risk. Recent coverage has focused on Compass as a real estate brokerage...

If you are wondering whether ServiceNow is priced fairly or offering value right now, the starting point is to look closely at what the current share price actually reflects about the business. The stock closed at US$90.49 recently, with returns of 9.6% decline over 7 days, 9.0% decline over 30 days, 38.6% decline year to date and 52.0% decline over the last year. This puts recent performance front and center for any valuation discussion. Recent coverage has focused on how this share price...

Nucor (NUE) opened Q1 2026 with revenue of about US$9.5b and basic EPS of US$3.25, setting a clear marker for how the year is starting. The company has seen quarterly revenue move from US$7.1b in Q4 2024 to US$7.8b in Q1 2025 and then to US$9.5b in Q1 2026. Basic EPS shifted from US$1.22 to US$0.67 over the Q4 2024 to Q1 2025 period before landing at US$3.25 in the latest quarter, giving investors plenty to weigh up on how margins are shaping the story. See our full analysis for Nucor. With...

Rambus (RMBS) has opened 2026 with Q1 revenue of US$180.2 million and basic EPS of US$0.55, setting the tone for how its growth story is feeding through to the bottom line. The company has seen quarterly revenue move from US$166.7 million in Q1 2025 to US$180.2 million in Q1 2026, while trailing twelve month EPS sits at US$2.13. This gives investors a clear read on both near term and rolling earnings power as they weigh the implications of slightly lower margins against the growth runway. See...

If you are wondering whether TAL Education Group at around US$10.77 is priced attractively or not, the key question is whether the current share price lines up with the underlying value of the business. The stock has seen mixed returns, with a 9.9% decline over the last 7 days, a 0.5% decline over 30 days, a 6.3% decline year to date, an 18.6% gain over the past year and a 104.8% gain over three years, set against an 80.8% loss over five years. Recent share price moves sit against a backdrop...

If you are wondering whether Avista at around US$41.21 is a fair price, a bargain, or something to be cautious about, this article is designed to help you frame that question clearly before you act. Over the recent period, Avista's share price closed at US$41.21, with returns of 2.1% over 7 days, 3.2% over 30 days, 6.4% year to date, 4.2% over 1 year, 9.8% over 3 years, and 13.1% over 5 years. Recent coverage of Avista has focused on its role in the Integrated Utilities space and how...

ACM Research shipped the world's first three-station rotating PECVD SiCN system, introducing a new architecture for advanced semiconductor manufacturing. The system is designed to improve film stability and process control for advanced back-end-of-line and packaging applications. This shipment marks a fresh addition to ACM Research's product lineup that has not been covered in recent company news. ACM Research (NasdaqGM:ACMR) is drawing attention with this new PECVD SiCN tool at a time when...

If you are wondering whether PTC Therapeutics at around US$70.26 is offering fair value or hidden upside, the starting point is to understand what the current market price is actually baking in. The stock has been volatile, with a 0.5% decline over the last 7 days, a 6.2% gain over the last 30 days, an 8.4% decline year to date, and a 41.9% return over the past year that sits alongside multi year returns of 27.8% over 3 years and 82.6% over 5 years. Behind these moves, investors have been...

United Parcel Service (UPS) opened 2026 with Q1 revenue of US$21.2b and basic EPS of US$1.02, setting the tone for how investors read the rest of the year’s earnings profile. The company has seen quarterly revenue move from US$25.3b in Q4 2024 to US$21.5b in Q1 2025 and US$21.2b in Q1 2026, while basic EPS over those same periods has gone from US$2.02 to US$1.40 and then to US$1.02. This puts more focus on how efficiently UPS converts its top line into profit as margins come under closer...

It's been a good week for Sierra Bancorp ( NASDAQ:BSRR ) shareholders, because the company has just released its latest...

If you are wondering whether Tesla's share price still reflects the story you have in mind, this article focuses on what the current market price might imply about the company's value. Tesla recently closed at US$376.02, with returns of 3.9% over 30 days, a 28.8% gain over 1 year, 134.6% over 3 years, and 67.5% over 5 years. Year to date the stock is down 14.2%, and over the last 7 days it has declined 2.7%. Recent headlines have continued to focus on Tesla's role as a major electric vehicle...

Simpson Manufacturing (SSD) has opened 2026 with Q1 revenue of US$588 million and basic EPS of US$2.14, setting the tone after a year in which trailing twelve month revenue reached US$2.4 billion and EPS came in at US$8.55. Over recent quarters the company has seen revenue range from US$539 million to US$631 million and EPS between US$1.32 and US$2.59. This gives investors a clear view of how the top and bottom line have been tracking into this latest print, with margins now a central focus...

If you are wondering whether SPS Commerce's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock last closed at US$55.29, with returns of 1.5% over 30 days but a 61.1% decline over the past year, which has many investors reassessing both potential upside and risk. Recent coverage has focused on SPS Commerce as a software name facing a very different market mood compared to a few years ago. There is...

In April 2026, Compass Therapeutics reported that its Phase 2/3 COMPANION-002 trial in advanced biliary tract cancer met the primary endpoint of overall response rate and a key secondary endpoint of progression-free survival for tovecimig plus paclitaxel versus paclitaxel alone, with no new safety concerns observed. An intriguing finding was that patients who crossed over from paclitaxel alone to the tovecimig combination lived longer than those who stayed on paclitaxel, despite initially...

TriNet Group (NYSE:TNET) has filed an omnibus or universal shelf registration statement. The filing allows the company to issue common and preferred stock, debt securities, warrants, depositary shares, purchase contracts, and units. The shelf registration can be used over time for fundraising, capital structure changes, or acquisition related financing. TriNet Group (NYSE:TNET) provides human resources solutions for small and medium sized businesses, so access to flexible funding tools can...